Skip to content
Oncology Research Hub

Houston, Texas

Cancer clinical trials in Houston, TX

624 cancer studies are recruiting participants at sites in Houston as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Houston at a glance

  • 624 studies are recruiting at a site in Houston.
  • By phase: Early Phase 1 (2), Phase 1 (140), Phase 1/2 (131), Phase 2 (130), Phase 2/3 (11), Phase 3 (100), Phase 4 (4), No phase (44), Observational (62). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (355), university, hospital or other (248), government (21).
  • By research area: Breast Cancer (180), Lung Cancer (179), Lymphoma (129), Prostate Cancer (64), Pancreatic Cancer (38), Melanoma (34).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in Houston

Basic details from each study's public record (the 30 most recently updated of 624). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Improving Comprehensive Care of Cancer Patients

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Baylor College of Medicine
    Study site
    Baylor College of Medicine
    Registry record
    NCT05323409 · updated
  2. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study sites
    The Methodist Hospital Research Institute · The University of Texas MD Anderson Cancer Center
    Registry record
    NCT06324357 · updated
  3. Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    LeonaBio
    Study sites
    Baylor College of Medicine · Harris Health System - Smith Clinic · MD Anderson Cancer Center
    Registry record
    NCT05696626 · updated
  4. A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Next Oncology - Houston
    Registry record
    NCT07488676 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Houston, TX on ClinicalTrials.gov.

Lung cancer studies recruiting in Houston

  1. LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    NovoCure GmbH
    Study site
    Houston Methodist Cancer Center
    Registry record
    NCT06216301 · updated
  2. A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

    • Phase 1/2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Tyligand Pharmaceuticals (Suzhou) Limited
    Study site
    MD Anderson Cancer Center
    Registry record
    NCT06385925 · updated
  3. A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 to 99
    • All sexes
    Sponsor
    Erasca, Inc.
    Study site
    The University of Texas MD Anderson Cancer Center
    Registry record
    NCT06983743 · updated
  4. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study sites
    MD Anderson · NEXT Oncology Houston
    Registry record
    NCT07277413 · updated
  5. A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Texas-MD Anderson Cancer Center ( Site 3283)
    Registry record
    NCT07513376 · updated
  6. A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

    • Phase 3
    • Ages 18 to 100
    • All sexes
    Sponsor
    Amgen
    Study sites
    Oncology Consultants PA · University of Texas MD Anderson Cancer Center
    Registry record
    NCT05920356 · updated
  7. A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Novelty Nobility, Inc.
    Study site
    The University of Texas MD Anderson Cancer Center
    Registry record
    NCT06805825 · updated
  8. A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    University of Texas MD Anderson Cancer Center
    Registry record
    NCT07063745 · updated
  9. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    University of Texas M. D. Anderson Cancer Center
    Registry record
    NCT07111520 · updated
  10. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    MD Anderson Cancer Center
    Registry record
    NCT07659782 · updated
  11. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Houston Methodist Hospital · Houston Methodist West Hospital
    Registry record
    NCT04267848 · updated
  12. Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers

    • Observational
    • All ages
    • All sexes
    Sponsor
    Lung Cancer Mutation Consortium
    Study site
    Baylor College of Medicine
    Registry record
    NCT04712877 · updated
  13. Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    The University of Texas MD Anderson Cancer Center
    Registry record
    NCT04886804 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Houston, TX on ClinicalTrials.gov.

Prostate cancer studies recruiting in Houston

  1. Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Texas Oncology - Gulf Coast ( Site 8002)
    Registry record
    NCT06136624 · updated
  2. Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Amgen
    Study site
    University of Texas MD Anderson Cancer Center
    Registry record
    NCT04221542 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Houston, TX on ClinicalTrials.gov.

Melanoma studies recruiting in Houston

  1. Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    M.D. Anderson Cancer Center
    Study site
    M D Anderson Cancer Center
    Registry record
    NCT04751396 · updated
  2. High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies

    • No phase
    • Ages 19 and older
    • All sexes
    Sponsor
    M.D. Anderson Cancer Center
    Study site
    M D Anderson Cancer Center
    Registry record
    NCT05053555 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Houston, TX on ClinicalTrials.gov.

Lymphoma studies recruiting in Houston

  1. Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    M.D. Anderson Cancer Center
    Study site
    M D Anderson Cancer Center
    Registry record
    NCT05011045 · updated
  2. Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    M.D. Anderson Cancer Center
    Study site
    MD Anderson Cancer Center
    Registry record
    NCT05676450 · updated
  3. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Houston Methodist Cancer Center ( Site 0154)
    Registry record
    NCT06717347 · updated
  4. Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT07109219 · updated
  5. A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Texas-MD Anderson Cancer Center ( Site 1323)
    Registry record
    NCT07634471 · updated
  6. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center · UT MD Anderson Cancer Center
    Registry record
    NCT04546399 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Houston, TX on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Houston

  1. Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

    • Phase 2
    • Ages 12 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Texas MD Anderson Cancer Center ( Site 0112)
    Registry record
    NCT04924075 · updated
  2. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    Investigative Site US011
    Registry record
    NCT07522073 · updated
  3. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    MD Anderson Cancer Center
    Registry record
    NCT07644559 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Houston, TX on ClinicalTrials.gov.

Ask about studies near Houston

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Texas

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call